retatrutide obesity phase 2 trial 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide study sees significant weight

Conclusion Concerns about Hims' GLP-1 strategy appear largely overblown The company is likely operating within legal boundaries and has a strong legal team Even if Novo sued for patent infringement, the most likely outcome would be a settlement with minimal negative impact In sum, it appears that concerns over the decision by Hims to continue to compound personalized versions of GLP-1 weight loss drugs past the enforcement deadlines set by the FDA are misplaced

Promoting collagen production Collagen is a crucial protein that provides structure and elasticity to the skin

PMID 38224592

23% (semaglutide) HbA1c: Greater reduction in prediabetes subgroup Physical Function: Improved SF-36 physical component score Safety Profile: GI Adverse Events: Nausea 47% (CagriSema) vs

[DOI] [PubMed] [Google Scholar] [108].Dushay J, Gao C, Gopalakrishnan GS, et al